The global cancer biological therapy market size is accounted at USD 124.44 billion in 2025 and is forecasted to hit around USD 249.17 billion by 2034, representing a CAGR of 8.02% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cancer Biological Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cancer Biological Therapy Market, by Type
8.1.1 Antibodies
8.1.1.1. Market Revenue and Forecast
8.1.2. Vaccines
8.1.2.1. Market Revenue and Forecast
8.1.3. Cancer Growth Blockers
8.1.3.1. Market Revenue and Forecast
8.1.4. Cytokines
8.1.4.1. Market Revenue and Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Forecast
9.1. Cancer Biological Therapy Market, by Phases
9.1.1. Phase I
9.1.1.1. Market Revenue and Forecast
9.1.2. Phases II
9.1.2.1. Market Revenue and Forecast
9.1.3. Phases III
9.1.3.1. Market Revenue and Forecast
10.1. Cancer Biological Therapy Market, by Distribution Channel
10.1.1. Specialized Cancer Treatment Centers
10.1.1.1. Market Revenue and Forecast
10.1.2. Hospitals & Clinics
10.1.2.1. Market Revenue and Forecast
10.1.3. Retail Pharmacies
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type
11.1.2. Market Revenue and Forecast, by Phases
11.1.3. Market Revenue and Forecast, by Distribution Channel
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type
11.1.4.2. Market Revenue and Forecast, by Phases
11.1.4.3. Market Revenue and Forecast, by Distribution Channel
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type
11.1.5.2. Market Revenue and Forecast, by Phases
11.1.5.3. Market Revenue and Forecast, by Distribution Channel
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type
11.2.2. Market Revenue and Forecast, by Phases
11.2.3. Market Revenue and Forecast, by Distribution Channel
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type
11.2.4.2. Market Revenue and Forecast, by Phases
11.2.4.3. Market Revenue and Forecast, by Distribution Channel
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type
11.2.5.2. Market Revenue and Forecast, by Phases
11.2.5.3. Market Revenue and Forecast, by Distribution Channel
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type
11.2.6.2. Market Revenue and Forecast, by Phases
11.2.6.3. Market Revenue and Forecast, by Distribution Channel
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type
11.2.7.2. Market Revenue and Forecast, by Phases
11.2.7.3. Market Revenue and Forecast, by Distribution Channel
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type
11.3.2. Market Revenue and Forecast, by Phases
11.3.3. Market Revenue and Forecast, by Distribution Channel
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type
11.3.4.2. Market Revenue and Forecast, by Phases
11.3.4.3. Market Revenue and Forecast, by Distribution Channel
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type
11.3.5.2. Market Revenue and Forecast, by Phases
11.3.5.3. Market Revenue and Forecast, by Distribution Channel
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type
11.3.6.2. Market Revenue and Forecast, by Phases
11.3.6.3. Market Revenue and Forecast, by Distribution Channel
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type
11.3.7.2. Market Revenue and Forecast, by Phases
11.3.7.3. Market Revenue and Forecast, by Distribution Channel
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type
11.4.2. Market Revenue and Forecast, by Phases
11.4.3. Market Revenue and Forecast, by Distribution Channel
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type
11.4.4.2. Market Revenue and Forecast, by Phases
11.4.4.3. Market Revenue and Forecast, by Distribution Channel
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type
11.4.5.2. Market Revenue and Forecast, by Phases
11.4.5.3. Market Revenue and Forecast, by Distribution Channel
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type
11.4.6.2. Market Revenue and Forecast, by Phases
11.4.6.3. Market Revenue and Forecast, by Distribution Channel
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type
11.4.7.2. Market Revenue and Forecast, by Phases
11.4.7.3. Market Revenue and Forecast, by Distribution Channel
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type
11.5.2. Market Revenue and Forecast, by Phases
11.5.3. Market Revenue and Forecast, by Distribution Channel
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type
11.5.4.2. Market Revenue and Forecast, by Phases
11.5.4.3. Market Revenue and Forecast, by Distribution Channel
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type
11.5.5.2. Market Revenue and Forecast, by Phases
11.5.5.3. Market Revenue and Forecast, by Distribution Channel
12.1. Incyte
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. ELI Lilly
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Merck
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Sanofi
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bayer
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Novartis International
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Roche
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Pfizer
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Bristol-Myers Squibb
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Amgen
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample